Galileo – Biotech Innovation Fund S USD

Reference Data

ISIN LU2226245095
Valor Number
Bloomberg Global ID
Fund Name Galileo – Biotech Innovation Fund S USD
Fund Provider IPConcept (Luxemburg) S.A. Zürich, Switzerland
Phone: +352 260248-1
E-Mail: info.lu@ipconcept.com
Web: www.ipconcept.com
Fund Provider IPConcept (Luxemburg) S.A.
Representative in Switzerland IPConcept (Schweiz) AG
Zürich
Phone: +41 044 224 32 09
Distributor(s) Bellecapital AG
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund charges a transaction fee (contribution towards expenses incurred in the investment of new assets)
Redemption Condition The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel)
Investment Strategy *** The objective of the investment policy for the sub-fund is to achieve an appropriate level of growth in the sub-fund currency while taking the investment risk into account. The sub-fund is actively managed. The composition of the portfolio is determined by the Fund Manager solely in accordance with the criteria laid down in the investment objectives / the investment policy, is regularly reviewed and, if necessary, adjusted. The sub-fund is not managed using an index as a benchmark.
Peculiarities

Fund Prices

Current Price * 56.07 USD 12.01.2026
Previous Price * 56.05 USD 09.01.2026
52 Week High * 60.08 USD 16.10.2025
52 Week Low * 32.42 USD 09.04.2025
NAV * 56.07 USD 12.01.2026
Issue Price * 56.07 USD 12.01.2026
Redemption Price * 56.07 USD 12.01.2026
Closing Price *
Indicative Minimum Price
Fund Assets *** 41,543,196
Unit/Share Assets *** 627,225
Trading Information SIX

Performance

YTD Performance -0.09% 30.12.2025
12.01.2026
YTD Performance (in CHF) +1.04% 30.12.2025
12.01.2026
1 month -1.99% 12.12.2025
12.01.2026
3 months -1.74% 13.10.2025
12.01.2026
6 months +34.14% 14.07.2025
12.01.2026
1 year +25.69% 13.01.2025
12.01.2026
2 years -5.76% 12.01.2024
12.01.2026
3 years -17.42% 12.01.2023
12.01.2026
5 years -62.62% 31.03.2021
12.01.2026

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Arcellx Inc 8.96%
Alnylam Pharmaceuticals Inc 7.42%
Krystal Biotech Inc 7.31%
Vertex Pharmaceuticals Inc 5.32%
BioNTech SE ADR 5.06%
Stoke Therapeutics Inc 4.61%
CARsgen Therapeutics Holdings Ltd Ordinary Shares 3.61%
Regeneron Pharmaceuticals Inc 3.59%
Gilead Sciences Inc 3.39%
CRISPR Therapeutics AG 2.94%
Last data update 30.06.2025

Cost / Risk

TER
TER date
Performance Fee ***
PTR
Max. Management Fee *** 0.60%
Ongoing Charges *** 1.07%
SRRI ***
SRRI date *** 31.12.2025

Breakdowns

Equity Countries ***

Equity Sectors ***

Bond Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)